EPS for Omnicell, Inc. (OMCL) Expected At $0.20

October 13, 2017 - By Louis Casey

 EPS for Omnicell, Inc. (OMCL) Expected At $0.20
Investors sentiment increased to 1.43 in Q2 2017. Its up 0.23, from 1.2 in 2017Q1. It is positive, as 12 investors sold Omnicell, Inc. shares while 58 reduced holdings. 19 funds opened positions while 81 raised stakes. 37.45 million shares or 0.69% less from 37.71 million shares in 2017Q1 were reported.
Thompson Davis And Inc stated it has 325 shares or 0.02% of all its holdings. Envestnet Asset, a Illinois-based fund reported 18,915 shares. Vanguard Gp accumulated 1.93 million shares. Thomson Horstmann & Bryant reported 0.74% stake. Regions holds 0.01% or 15,352 shares. Cap Impact Advsrs Limited Liability stated it has 0.42% in Omnicell, Inc. (NASDAQ:OMCL). Rhenman And Prns Asset Management Ab holds 0.58% or 94,231 shares in its portfolio. Westwood Hldgs Grp Inc holds 0.15% or 439,617 shares. Dimensional Fund Advsrs Lp invested 0.03% in Omnicell, Inc. (NASDAQ:OMCL). Kornitzer Capital Management Incorporated Ks has invested 0.1% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL). Tennessee-based First Mercantile has invested 0.08% in Omnicell, Inc. (NASDAQ:OMCL). Strs Ohio reported 0.02% stake. First National Bank Of Omaha owns 21,660 shares. Bb&T reported 0.01% stake. Ftb Advsr owns 900 shares.

Since May 9, 2017, it had 0 insider purchases, and 7 selling transactions for $4.88 million activity. PETERSMEYER GARY S also sold $91,097 worth of Omnicell, Inc. (NASDAQ:OMCL) shares. DREW J CHRISTOPHER had sold 10,625 shares worth $435,308. $666,988 worth of Omnicell, Inc. (NASDAQ:OMCL) shares were sold by JOHNSTON DAN S. $504,123 worth of Omnicell, Inc. (NASDAQ:OMCL) was sold by Judson James T.

Wall Street await Omnicell, Inc. (NASDAQ:OMCL) to release earnings on October, 26. Analysts forecast earnings per share of $0.20, down exactly $0.10 or 33.33 % from 2014’s $0.3 EPS. The expected OMCL’s profit could reach $7.48 million giving the stock 64.19 P/E in the case that $0.20 earnings per share is reported. After posting $0.02 EPS for the previous quarter, Omnicell, Inc.’s analysts now forecast 900.00 % EPS growth. The stock decreased 0.39% or $0.2 during the last trading session, reaching $51.35. About 142,605 shares traded. Omnicell, Inc. (NASDAQ:OMCL) has risen 33.21% since October 13, 2016 and is uptrending. It has outperformed by 16.51% the S&P500.

Omnicell, Inc. (NASDAQ:OMCL) Ratings Coverage

Among 9 analysts covering Omnicell (NASDAQ:OMCL), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Omnicell had 16 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, July 25. The rating was maintained by Oppenheimer on Friday, July 28 with “Buy”. On Monday, November 16 the stock rating was maintained by Topeka Capital Markets with “Buy”. Sidoti upgraded Omnicell, Inc. (NASDAQ:OMCL) on Monday, September 28 to “Buy” rating. The stock of Omnicell, Inc. (NASDAQ:OMCL) has “Buy” rating given on Tuesday, December 6 by Benchmark. The stock of Omnicell, Inc. (NASDAQ:OMCL) earned “Buy” rating by FBR Capital on Thursday, September 3. FBR Capital maintained Omnicell, Inc. (NASDAQ:OMCL) on Friday, October 30 with “Outperform” rating. The firm earned “Buy” rating on Thursday, January 19 by Dougherty & Company. As per Monday, June 12, the company rating was maintained by Cantor Fitzgerald. The firm has “Hold” rating given on Friday, July 28 by Piper Jaffray.

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The company has market cap of $1.92 billion. It operates through two divisions: Automation and Analytics, and Medication Adherence. It currently has negative earnings. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software.

More notable recent Omnicell, Inc. (NASDAQ:OMCL) news were published by: Prnewswire.com which released: “Omnicell Announces Inaugural “Inspired by Care” Awards” on October 12, 2017, also Prnewswire.com with their article: “Frost & Sullivan Names Omnicell as Global Smart Hospitals’ Pharmacy Automation …” published on October 05, 2017, Investorplace.com published: “Omnicell (OMCL) Retains Buy Ranking” on October 05, 2017. More interesting news about Omnicell, Inc. (NASDAQ:OMCL) were released by: Prnewswire.com and their article: “Prime Healthcare Expands Existing Partnership with Omnicell to Serve a …” published on September 28, 2017 as well as Nasdaq.com‘s news article titled: “Omnicell (OMCL) Gains on Product Launches, Global Expansion” with publication date: September 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.